Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $382.00

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned a consensus rating of “Moderate Buy” from the four ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $382.00.

Several research firms have issued reports on MEDP. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and increased their price target for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Finally, Robert W. Baird upped their price target on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th.

Insider Activity

In related news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. In the last three months, insiders sold 189,340 shares of company stock worth $76,651,647. 20.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of MEDP. BlackRock Inc. grew its holdings in shares of Medpace by 0.9% during the first quarter. BlackRock Inc. now owns 3,792,694 shares of the company’s stock worth $620,448,000 after purchasing an additional 35,121 shares during the last quarter. Wasatch Advisors Inc. increased its stake in shares of Medpace by 12.1% in the first quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock valued at $446,338,000 after buying an additional 294,103 shares during the period. Vanguard Group Inc. raised its position in shares of Medpace by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after acquiring an additional 142,591 shares during the last quarter. State Street Corp lifted its position in shares of Medpace by 2.5% in the 1st quarter. State Street Corp now owns 899,855 shares of the company’s stock worth $147,207,000 after purchasing an additional 21,868 shares during the period. Finally, Riverbridge Partners LLC boosted its position in Medpace by 6.7% during the fourth quarter. Riverbridge Partners LLC now owns 683,943 shares of the company’s stock valued at $209,649,000 after acquiring an additional 43,036 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 2.1 %

Shares of NASDAQ MEDP opened at $374.32 on Friday. Medpace has a 1 year low of $185.43 and a 1 year high of $419.42. The firm has a market capitalization of $11.60 billion, a PE ratio of 42.15, a price-to-earnings-growth ratio of 2.03 and a beta of 1.38. The firm’s 50-day moving average is $394.87 and its 200-day moving average is $319.06.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.24. The firm had revenue of $498.40 million for the quarter, compared to analyst estimates of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The company’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.12 earnings per share. As a group, equities research analysts anticipate that Medpace will post 10.53 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.